C12R 2001/42
Salmonella
C12R2001/42 (Salmonella) appears on 84 US grants and 115 published applications in this corpus.
Search patents in C12R- Granted patents
- 84
- Published applications
- 115
- Assignees
- 81
- Inventors
- 259
- Latest grant
- 6 Oct 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1979 | 1 | 0 |
| 1980 | 0 | 0 |
| 1981 | 0 | 0 |
| 1982 | 0 | 0 |
| 1983 | 0 | 0 |
| 1984 | 0 | 0 |
| 1985 | 1 | 0 |
| 1986 | 0 | 0 |
| 1987 | 0 | 0 |
| 1988 | 1 | 0 |
| 1989 | 1 | 0 |
| 1990 | 0 | 0 |
| 1991 | 1 | 0 |
| 1992 | 1 | 0 |
| 1993 | 1 | 0 |
| 1994 | 1 | 0 |
| 1995 | 4 | 0 |
| 1996 | 1 | 0 |
| 1997 | 8 | 0 |
| 1998 | 4 | 0 |
| 1999 | 5 | 0 |
| 2000 | 3 | 0 |
| 2001 | 1 | 0 |
| 2002 | 2 | 0 |
| 2003 | 0 | 1 |
| 2004 | 1 | 2 |
| 2005 | 0 | 1 |
| 2006 | 2 | 3 |
| 2007 | 1 | 0 |
| 2008 | 1 | 2 |
| 2009 | 0 | 1 |
| 2010 | 1 | 0 |
| 2011 | 1 | 1 |
| 2012 | 0 | 2 |
| 2013 | 0 | 1 |
| 2014 | 1 | 1 |
| 2015 | 0 | 3 |
| 2016 | 2 | 7 |
| 2017 | 6 | 2 |
| 2018 | 1 | 4 |
| 2019 | 3 | 4 |
| 2020 | 3 | 4 |
| 2021 | 2 | 4 |
| 2022 | 3 | 15 |
| 2023 | 5 | 9 |
| 2024 | 4 | 16 |
| 2025 | 5 | 15 |
| 2026 | 6 | 17 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Recent patents
- Tumor-targeting Salmonella gallinarum strain and use thereof6 Oct 2026US 12,751,978 B2Industry Foundation of Chonnam National University
- Attenuated Salmonella gallinarum expressing FliC or FliC-hIL2 and uses thereof11 Aug 2026US 12,702,685 B2Odysseus Bio Co., Ltd.
- Compositions and methods of treatment comprising tumor-targeting bacteria and chemotherapy or immunotherapy agent9 Jun 2026US 12,648,970 B2The Curators of the University of Missouri
- Live self-destructing bacterial adjuvants to enhance induction of immunity19 May 2026US 12,629,417 B2University of Florida Research Foundation, Inc.
- Recombinant strains and medium formulation for enhancing secretion titer using a type III secretion system3 Mar 2026US 12,565,519 B2Northwestern University
- Recombinant expression vector for interferon-beta secretion and attenuated salmonella strain transformed by means of same8 Oct 2026US 2026/0306554 A1The Industry & Academic Cooperation in Chungnam National University (IAC)
- Recombinant expression vector for secreting interleukin-12, and attenuated salmonella strain transformed therewith8 Oct 2026US 2026/0306555 A1The Industry & Academic Cooperation in Chungnam National University (IAC)
- Intracellular Delivery of Therapeutic Cargos and Viral RNAS by Engineered Salmonella17 Sep 2026US 2026/0272995 A1The Trustees of Columbia University in the City of New York
- Delivery of protein extracellularly10 Sep 2026US 2026/0263370 A1
- Bacteriophage, composition, and method for controlling bacteria of the genus salmonella27 Aug 2026US 2026/0248865 A1Kaneka Corporation
Most cited
By later US patents
- Avirulent microbes and uses therefor: Salmonella typhi109US 5,387,744 AWashington University · 1995
- Avirulent microbes and uses therefor: salmonella typhi103US 5,294,441 AWashington University · 1994
- Vaccines containing avirulent phop-type microorganisms101US 5,424,065 AWashington University · 1995
- Novel non-reverting shigella live vaccines87US 5,077,044 AThe Board of Trustees of the Leland Stanford Jr. University · 1991
- Selective maintenance of a recombinant gene in a population of vaccine cells70US 5,672,345 AWashington University · 1997